Deinove released its H119 results on 26 September 2019. The company reported progress with most of its projects in the pipeline, which is well diversified across a number of different programmes and technologies. We believe the antibiotic asset DNV3837 is the most valuable, as it is a pure drug development programme. Deinove has been preparing for the Phase II efficacy trial in C. diff infections and the first patient should be recruited in the coming weeks. The company also reported multiple
16 Oct 2019
Deinove - Steady progress on all fronts
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Deinove - Steady progress on all fronts
- Published:
16 Oct 2019 -
Author:
Dr Jonas Peciulis -
Pages:
7
Deinove released its H119 results on 26 September 2019. The company reported progress with most of its projects in the pipeline, which is well diversified across a number of different programmes and technologies. We believe the antibiotic asset DNV3837 is the most valuable, as it is a pure drug development programme. Deinove has been preparing for the Phase II efficacy trial in C. diff infections and the first patient should be recruited in the coming weeks. The company also reported multiple